Blog

Major developments in European HealthTech this week have been dominated by major funding rounds in biotech, significant regulatory alignment and continued investment in digital health.Here are the key highlights:1. Record-Breaking Funding Rounds German Biotech Tubulis secured a €308 million Series C financing round. This is reported as the largest Series C ever raised by a European biotech and the largest private financing globally for an antibody-drug conjugate (ADC) developer. The funds will advance their cancer therapies, including a lead candidate in a Phase I/IIa study.Finnish HealthTech Oura (the smart ring maker) raised substantial fresh funding, valuing the company at around $11 billion, and plans to accelerate AI and product innovation globally.British investor Spex Capital announced the first €30 million commitment to its flagship €100 million Venture HealthTech Fund, aimed at global early-stage HealthTech startups.2. Regulatory &amp; International Cooperation The UK's MHRA (Medicines and Healthcare products Regulatory Agency) and the US FDA (Food and Drug Administration) announced a deeper collaboration on medical technologies and AI. This alliance aims to harmonize regulation and create new reliance routes to speed up safe access to innovative devices in the UK.The EU Data Act's obligations became applicable this week, which is a major regulatory cornerstone designed to unlock the value of data across sectors, including healthcare and life sciences, by establishing rules on data access and use.3. Product Launches and AI Adoption &nbsp; Medtronic launched its VitalFlow ECMO system in Europe, a new one-system platform for critical care.Vektor Medical secured the CE mark for vMap, an AI-assisted, non-invasive arrhythmia mapping product, allowing its entry into the EU market.There's ongoing focus on AI integration in clinical settings, with reports on major NHS trusts pushing forward with comprehensive AI strategy roadmaps.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

This Week in European HealthTech - Week 3 October 2025

Brain with AI chip inside. Artificial intelligence, Brain science, Neuro system

Artificial Intelligence (AI) is fundamentally reinventing mental healthcare by addressing critical issues of accessibility, efficiency, and personalisation, moving the field towards a more proactive, data-driven model. AI acts primarily as a powerful augmentative tool for human clinicians, rather than a replacement for them.Key Transformations Driven by AIAI is transforming mental healthcare across diagnosis, treatment, and resource management:1. Enhanced and Early DiagnosisAI excels at processing large, complex datasets to identify subtle indicators of mental health conditions earlier than traditional methods.Predictive Analytics: AI algorithms analyse data from Electronic Health Records (EHRs), speech patterns, social media activity, and wearable devices to identify individuals at high risk for conditions like depression, anxiety, or psychosis, enabling proactive intervention. Objective Screening: Natural Language Processing (NLP) analyses text and speech for linguistic markers (e.g., changes in tone, word choice, and rhythm) that correlate with mental states. Facial expression analysis can also detect subtle emotional cues. Streamlining Clinical Workflow: AI assists clinicians by sifting through complex patient data for relevant information, supporting quicker, more accurate diagnostic decisions.2. Personalised and Accessible InterventionsAI increases the reach and tailoring of mental health support.AI-Powered Chatbots and Virtual Assistants: Tools like Woebot or Wysa offer 24/7, non-judgmental support, often utilising principles of Cognitive Behavioural Therapy (CBT).They provide real-time coping strategies, emotional check-ins, and interim support between human sessions, significantly improving accessibility and reducing stigma.Tailored Treatment Plans: AI analyses a patient's unique history, genetics, symptoms, and response to previous therapies to recommend the most effective, personalised combination of medication and therapeutic modalities.Virtual Reality (VR) Therapy: AI enhances VR exposure therapy for phobias and Post-Traumatic Stress Disorder (PTSD) by dynamically adjusting virtual scenarios based on the patient's real-time physiological and psychological responses.3. Monitoring and AdherenceAI provides continuous, real-time tracking that vastly improves care management.Continuous Monitoring: Wearable devices and mobile apps, integrated with AI, monitor physiological signals (e.g., heart rate variability, sleep patterns) and behavioural data (e.g., activity levels) to track a patient’s well-being and detect early signs of relapse.Improving Compliance: AI can identify behaviuoral patterns suggesting non-adherence to treatment (medication or therapy) and send personalised reminders or alerts to both the patient and the care provider.The Future: Augmented Human CareThe future of mental healthcare is not AI replacing therapists, but rather a model of "Augmented Human Care" where technology supports and extends the capacity of clinicians. AI will handle data-intensive tasks and routine support, freeing human professionals to focus on the essential, complex, and relational aspects of therapy and treatment. This collaboration holds the promise of making mental health support more accessible, accurate, and truly individualised worldwide.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Reinventing mental healthcare in the age of AI

Nelson Advisors invited to speak at the Health Tech Forward 2025 Conference in Barcelona: ‘Health Data Under Attack: Emerging Vulnerabilities in Healthcare’ Panel.Partner, Lloyd Price will join Laura Busquet Raich and others exploring the key vulnerabilities in health tech, medtech,and AI across Europe.‘Health Data Under Attack: Emerging Vulnerabilities in Healthcare’ PanelWith digital innovation taking over healthcare, new risks are emerging. It affects all market sectors – from diagnostics to medical devices and health apps we use. That comes down to sensitive patient data moving through increasingly complex systems. This panel will examine vulnerabilities in health tech, medtech, and AI. Experts will discuss ransomware, device security gaps, and data misuse. Join in to explore how innovation and security must advance together to protect patients and sustain trust.Health Tech Forward 2025Location: Palau de Congressos de Barcelona in Barcelona, Spain. Dates: December 3-4, 2025. Focus: Europe's premier event for health tech innovation and investment, featuring keynote speeches, dynamic panel discussions, and targeted 1:1 networking opportunities. Panel Topic Context: The panel falls under the track/topic of cybersecurity, compliance, and collaboration(often referred to as the "3C's"), addressing the critical security challenges facing the healthcare sector as it adopts new technologies.The conference agenda often covers themes ranging from AI insights and clinical breakthroughs to consumer tech &amp; wellness.<a data-mce-href="https://healthtechforward.com" href="https://healthtechforward.com" title="https://healthtechforward.com" target="_blank" rel="noopener">https://healthtechforward.com</a>

Nelson Advisors invited to speak at the Health Tech Forward 2025 Conference in Barcelona

The VIP Investor Programme at the Global Health Exhibition 2025 in Riyadh is an exclusive, invitation-only initiative designed to connect various types of investors with high-impact investment, partnership, and joint venture opportunities in Saudi Arabia's rapidly growing healthcare sector. The program aligns with the goals of Saudi Vision 2030 to transform the health sector.Key Programme Details The program is aimed at decision-makers from entities like Investment Firms, Venture Capital (VCs), Corporate VCs, and Family Offices who are interested in the Saudi healthcare landscape.Benefits: Participants receive a number of exclusive advantages, including:&gt; High-impact networking and matchmaking opportunities. &gt; Face-to-face meetings with representatives from the Ministries of Health and Investment. &gt; Access to the Investor Forum, which covers topics like investing in the Kingdom of Saudi Arabia (KSA) and the future of healthcare. &gt; Connections with key stakeholders and opportunities to explore the investment landscape and identify potential partners. &gt; Access to investor lounges and exclusive networking events.Global Health Exhibition 2025 Event Information The exhibition itself serves as a vital platform for attracting capital and showcasing innovation in line with the Kingdom's goals.Dates: October 27 – 30, 2025 (Show timings are generally 10 am – 7 pm on the first three days and 10 am – 6 pm on the last day). Venue: Riyadh Exhibition and Convention Center (Malham), Riyadh, Saudi Arabia. Theme: "Invest in Health." Key Focus Areas:&nbsp;Digital Health Life Sciences Medical Devices Imaging &amp; Radiology Laboratory Startups WellnessThe Investor Programme is a core component of the exhibition, highlighting the Venture Forum which delves into investment strategies, emerging trends, and key regulatory updates in the medical technology market. The 2024 edition alone recorded investments exceeding SAR 50 billion, underscoring the event's significance for global investor confidence in the Saudi market.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title=" lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener"> lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors invited to join the VIP Investor Programme at the Global Health Exhibition 2025

A wooden abacus with black and white beads sits on a green table. The abacus is old and has a vintage feel to it

As of October 2025, European MedTech and HealthTech valuation multiples are showing steady resilience and selective optimism, following a cautious rebound that began in early 2025. The overall sentiment is moderately bullish for high-quality, profitable, and AI-driven businesses, while smaller or unprofitable firms continue to face compressed valuations.MedTech Valuation Multiples (October 2025)EV/Revenue: The average revenue multiple for European MedTech companies is between 4x–6x, with standout innovators in areas like AI diagnostics, telemedicine, and digital surgery achieving 6x–8x revenue multiples due to premium strategic and private equity demand.&nbsp; EV/EBITDA: Profitable MedTech firms typically achieve 10x–14x EBITDA, slightly higher than 2024 averages (10x–12.5x), reflecting cautious optimism and strong M&amp;A competition for scalable companies.&nbsp; Key valuation drivers: Integration of AI and digital workflow tools within existing clinical systems.Consolidation through M&amp;A by large medical device players. Maturing regulatory clarity under the EU AI Act and European Health Data Space.HealthTech Valuation Multiples (October 2025)EV/Revenue: The average HealthTech revenue multiple is 4.8x year-to-date (YTD 2025), within a 4x–6x general range. Innovative sub-sectors—particularly AI-driven platforms, telehealth, and advanced analytics—routinely trade between 6x–8x revenue.&nbsp; EV/EBITDA: Profitable digital health firms are valued around 10x–14x EBITDA, aligning with the broader MedTech range.&nbsp; ARR Multiples: For recurring-revenue or SaaS-oriented HealthTechs, EV/ARR multiples span roughly 6x–20x, reflecting premium pricing for stable subscription-based models.&nbsp; Drivers of valuation: Proven profitability and high recurring revenue share. Alignment with value-based care and measurable cost efficiency. Data monetisation capability and secure interoperability with EHR systems. Strategic acquisitions by both private equity funds and large healthcare conglomerates.In summary, European MedTech and HealthTech valuations have stabilised around healthy mid-single-digit revenue multiples and low-teens EBITDA multiples, with continued robust interest in companies that combine profitability, AI integration, and value-based healthcare alignment.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

European MedTech and HealthTech valuation multiples - October 2025

Development to success and motivation in 2026.Growth and development chart of company in new year 2026. Planning,opportunity, challenge and business strategy in new year 2026.

Five dominant mega trends are forceast to &nbsp;shape the European HealthTech and MedTech landscape for 2026. The year marks a critical nexus where groundbreaking technological acceleration meets definitive regulatory enforcement, primarily through the EU AI Act and the European Health Data Space (EHDS) regulation. Success in 2026 will be defined by strategic regulatory compliance, the adoption of interoperable data standards (Observational Medical Outcomes Partnership, or OMOP, and Fast Healthcare Interoperability Resources, or FHIR), and the effective leveraging of EU strategic funding (European Defence Fund, or EDF, and Strategic Technologies for Europe Platform, or STEP). The analysis predicts a decisive shift toward Regulatory Infrastructure Plays (Dynamic Consent and Data Flow solutions) and Clinically Validated, High-Growth Disruptors (Pulsed-Field Ablation, Ambient Clinical Intelligence). The primary strategic imperative for executives operating in this ecosystem will be efficiently transforming regulatory burden into a potent competitive filter and an M&amp;A catalyst, separating scalable innovators from regulatory-strained ventures.Five predictions for European HealthTech and MedTech in 2026, based on the identified trends, are:1) Electric Medicine (Bioelectronic Medicine): Continued expansion of neurotechnology and bioelectronic devices, moving beyond deep-brain stimulation (DBS) to include more sophisticated Brain-Computer Interfaces (BCIs) and non-invasive neuromodulation. This will be an area of high growth and innovation, increasingly used for treatment of chronic conditions.2) SleepTech (Integrated Sleep and Digital Health): The convergence of professional sleep medicine and consumer wearables. This will be driven by dedicated events like "Sleep Europe 2026," and is part of the broader trend of remote patient monitoring and personalized healthcare, with advanced wearables monitoring vitals and sleep patterns to predict health issues. 3) Ambient Clinical Intelligence (AI-driven Workflow Automation): Widespread adoption of Ambient Voice Technologies (AVTs) and AI scribes in European clinical settings to reduce administrative burden and burnout. This trend will be tightly regulated by the EU AI Act and national health service guidelines to ensure safety, data privacy, and patient consent are managed transparently. 4) Defence MedTech (Supply Chain and Crisis Resilience): A heightened focus on supply chain resilience and strategic preparedness in medical devices. While not strictly "defence," the geo-political and supply chain challenges highlighted by MedTech Europe will drive investment in secure, local manufacturing, and the development of technologies that support rapid response and crisis management, aligning with broader EU health security goals. 5) Dynamic Data Consent Models (European Health Data Space - EHDS): The implementation and maturation of the European Health Data Space (EHDS) will be the key driver. This is expected to establish consistent frameworks for the secondary use of health data for research and innovation. This will necessitate the move toward more granular, user-controlled, or "dynamic" consent models, ensuring compliance with GDPR while enabling data sharing for AI development and personalized medicine. Full enforcement of the AI Act and new data legislation timelines (such as the Data Act and national laws) in 2026 will enforce this shift.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

This Week in European HealthTech - Week 3 October 2025

Reinventing mental healthcare in the age of AI

Nelson Advisors invited to speak at the Health Tech Forwa...

Nelson Advisors invited to join the VIP Investor Programm...

European MedTech and HealthTech valuation multiples - Oct...

Five MegaTrends and Predictions for European HealthTech a...